ALT Q4 2021 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$353M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+41.7% YoY

Gross Profit

-$18M-542.2% margin

Operating Income

-$24M-731.9% margin

Net Income

-$24M-729.0% margin

EPS (Diluted)

$-0.57

QoQ Revenue Growth

+1974.1%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$219M

Total Liabilities

$20M

Stockholders' Equity

$199M

Cash & Equivalents

$190M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+41.7%
Gross Profit	-$18M	-$13M	-40.0%
Operating Income	-$24M	-$11M	-123.1%
Net Income	-$24M	-$11M	-124.9%

Revenue Segments

Grant

$3M100%